Gestational Diabetes Mellitus in Pregnancy, Hyperprolactinemia Pregnancy
Conditions
Keywords
Gestational Diabetes Mellitus, Prolactin, Insulin resistance, Fibroblast growth factor 21
Brief summary
Prolactin (PRL) and PRL receptor (PRLR) signaling has been validated to play an important role in the modulation of glucolipid metabolism. However, the role of serum PRL levels in gestational diabetes mellitus (GDM) remains unclear. The investigators aimed to explore the possible influence of serum PRL within or without normal range on the development of GDM.
Interventions
DIAGNOSTIC_TESTBlood sampling
blood sampling
Sponsors
Shen Qu
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* aged 18 to 45 years * completed a 75-g oral glucose tolerance test (OGTT) * females with pregnancy
Exclusion criteria
* severe liver and renal dysfunction, preexisting heart disease, malignancy, or endocrine diseases such as pituitary adenoma and hypogonadism * mental illness * genetic disease * current or previous treatment that might affect PRL and insulin secretion * diabetes before pregnancy * loss to follow-up, or withdrawal from the study * unable to understand and comply with the study protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Gestational diabetes mellitus (GDM) | 2019-2023 | GDM is defined as a glucose intolerance resulting in hyperglycaemia of variable severity with onset during pregnancy. It can be diagnosed by the criteria: a fasting plasma glucose (FPG) concentration of O126 mg/dl on two separate occasions or a random blood glucose concentration of O200 mg/dl on two separate occasions. |
| PRL | 2019-2023 | serum prolactin level |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Insulin resistance (IR) | 2019-2023 | It was considered to be IR if HOMA-IR \>2.5 |
| HOMA-IR | 2019-2023 | It was calculated as: fasting plasma glucose (FPG) x fasting insulin (FINS)/22.5 |
| OGTT | 2019-2023 | OGTT was performed after an overnight fasting in each patient and blood samples were taken at 0, 30, 60, 120, and 180 min to determine the concentrations of plasma glucose. |
Countries
China
Outcome results
None listed